Condition
MG
Total Trials
4
Recruiting
3
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Early P 1 (2)
P 2 (1)
Trial Status
Recruiting3
Withdrawn1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07284420Phase 2Recruiting
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
NCT07294170Recruiting
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
NCT06548620Early Phase 1Withdrawn
A Study of RD06-04 in Patients With Active Autoimmune Diseases
NCT06775912Early Phase 1Recruiting
Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases
Showing all 4 trials